+1 202 637 6414
+1 202 637 5910
Partner, Washington, D.C.
Christie Bloomquist is a partner in the Health practice in Washington, D.C. office of Hogan Lovells. Christie’s practice focuses on advising pharmaceutical and medical device companies on fraud and abuse compliance and pricing issues as well as on other regulatory and policy matters, including aspects of the Affordable Care Act.
Prior to joining Hogan Lovells, Christie served as Senior Director, Federal Government Affairs, with AstraZeneca Pharmaceuticals LP in Washington, D.C. In this role, she was the chief healthcare lobbyist for AstraZeneca and represented the company’s interests during the passage and implementation of the Affordable Care Act and during deficit reduction negotiations last summer. Bloomquist worked closely with commercial business leaders and industry senior executives throughout her tenure at AstraZeneca. In her previous roles in private practice, she advised pharmaceutical and medical device manufacturers and entities in the delivery supply chain on a vast array of fraud and abuse (principally Anti-Kickback and Stark), compliance, and reimbursement issues.
Bloomquist also has advised manufacturers on the full range of compliance and policy issues, including bundled discounts, grants, and sales and marketing activities. Additionally, she has provided guidance on drug pricing issues (Medicaid rebate program and Part B pricing calculations) and assisted clients in preparing annual reports required under Corporate Integrity Agreements.
Hogan Lovells Publications
31 October 2013
"HHS: Qualified Health Plans Are Not 'Federal Health Care Programs'." Health Alert, Hogan Lovells
23 July 2013
"340B Program: Health Resources and Services Administration (HRSA) Releases Final Rule on Orphan Drug Exclusion." Health, Pharmaceutical and Biotechnology Alert, Hogan Lovells
08 July 2013
"OIG approves tiered rebate program based on combination of purchases." Health Alert, Hogan Lovells
09 May 2013
"HHS-OIG updates Special Advisory Bulletin on effect of exclusion from federal healthcare programs." Health Alert, Hogan Lovells
28 March 2013
"CMS provides opportunity to comment on certain elements of Sunshine regulations." Health Alert, Hogan Lovells
07 February 2013
"The Sunshine Act takes effect: Key provisions of the final rule." Health Alert, Hogan Lovells
06 September 2012
"Vermont offers limited disclosure law amnesty to manufacturers of medical devices and biologics." Health Alert, Hogan Lovells
23 July 2012
"Massachusetts amends anti-kickback law to allow certain prescription drug coupons: Implementation issues." Health Alert, Hogan Lovells
10 July 2012
"Massachusetts relaxes restrictions on meals for covered practitioners and device training." Health Alert, Hogan Lovells
10 July 2012
"Massachusetts amends anti-kickback law to allow certain prescription drug coupons." Health Alert, Hogan Lovells
09 July 2012
"President to sign Food and Drug Administration Safety and Innovation Act: Summary of certain key provisions." Health Alert, Hogan Lovells